Compare · IMNN vs NVS
IMNN vs NVS
Side-by-side comparison of Imunon Inc. (IMNN) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNN and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 38153.7x IMNN ($7.7M).
- IMNN has been more active in the news (16 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Imunon Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $7.7M
- $293.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 1
- Recent ratings
- 0
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest IMNN
- Executive Chairman of Board Tardugno Michael H was granted 4,410 shares, increasing direct ownership by 7% to 64,396 units (SEC Form 4)
- SEC Form 3 filed by new insider Blacher Joshua
- General Counsel and Corp Sec Eylward Susan was granted 920 shares and sold $1,730 worth of shares (920 units at $1.88) (SEC Form 4)
- Chief Medical Officer Faller Douglas Vincent was granted 1,308 shares, increasing direct ownership by 6% to 23,204 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 2,534 shares, increasing direct ownership by 3% to 76,722 units (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Medical Officer Faller Douglas Vincent was granted 21,896 shares (SEC Form 4)
- General Counsel and Corp Sec Eylward Susan was granted 14,696 shares and sold $20,674 worth of shares (11,800 units at $1.75) (SEC Form 4)
- Executive Chairman of Board Tardugno Michael H was granted 42,519 shares, increasing direct ownership by 243% to 59,986 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 67,150 shares, increasing direct ownership by 954% to 74,188 units (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG